Holmium-166 Radioembolization: Current Status and Future Prospective

Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 (Ho-166) caught the experts' attention due to its imaging possibilities. Being not only a beta, but also a gamma emitter and a lanthanide, Ho-166 can be imaged using single-photon emission computed tomography and magnetic resonance imaging, respectively. Another advantage of Ho-166 is the possibility to perform the scout and treatment procedure with the same particle. This prospect paves the way to an individualized treatment procedure, gaining more control over dosimetry-based patient selection and treatment planning. In this review, an overview on Ho-166 liver radioembolization will be presented. The current clinical workflow, together with the most relevant clinical findings and the future prospective will be provided.

Automated summary

Since its suggestion as a possible option for liver radioembolization treatment, holmium-166 (Ho-166) has attracted attention due to its imaging possibilities and potential for individualized treatment. Ho-166 can be imaged using single-photon emission computed tomography and magnetic resonance imaging, and also allows for both scout and treatment procedures with the same particle.